Two Sigma Advisers LP Lowers Holdings in Retrophin Inc (RTRX)

Two Sigma Advisers LP lessened its stake in Retrophin Inc (NASDAQ:RTRX) by 48.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,700 shares of the biopharmaceutical company’s stock after selling 34,300 shares during the quarter. Two Sigma Advisers LP owned about 0.09% of Retrophin worth $773,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of RTRX. Consonance Capital Management LP increased its position in Retrophin by 4.0% in the 4th quarter. Consonance Capital Management LP now owns 3,644,438 shares of the biopharmaceutical company’s stock valued at $76,788,000 after acquiring an additional 138,834 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Retrophin by 8.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 896,815 shares of the biopharmaceutical company’s stock valued at $22,322,000 after acquiring an additional 71,562 shares in the last quarter. Bank of Montreal Can increased its position in Retrophin by 51.5% in the 4th quarter. Bank of Montreal Can now owns 181,416 shares of the biopharmaceutical company’s stock valued at $3,823,000 after acquiring an additional 61,634 shares in the last quarter. GW&K Investment Management LLC increased its position in Retrophin by 40.7% in the 4th quarter. GW&K Investment Management LLC now owns 190,545 shares of the biopharmaceutical company’s stock valued at $4,015,000 after acquiring an additional 55,130 shares in the last quarter. Finally, Virtus Fund Advisers LLC acquired a new stake in Retrophin in the 4th quarter valued at about $933,000.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:RTRX opened at $26.89 on Tuesday. Retrophin Inc has a one year low of $15.55 and a one year high of $28.25. The company has a quick ratio of 3.74, a current ratio of 3.80 and a debt-to-equity ratio of 0.15. The company has a market cap of $1,083.76, a PE ratio of -17.93 and a beta of 1.05.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.20). Retrophin had a negative return on equity of 13.98% and a negative net margin of 38.55%. The business had revenue of $42.18 million for the quarter, compared to analyst estimates of $42.20 million. equities research analysts forecast that Retrophin Inc will post -1.6 earnings per share for the current fiscal year.

RTRX has been the subject of several research reports. Zacks Investment Research upgraded shares of Retrophin from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 4th. ValuEngine upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. BidaskClub cut shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Saturday, December 30th. Finally, BMO Capital Markets lowered their price target on shares of Retrophin from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Wednesday, April 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $43.00.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.chaffeybreeze.com/2018/04/17/two-sigma-advisers-lp-lowers-holdings-in-retrophin-inc-rtrx.html.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply